Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

hCDC4 gene mutations in endometrial cancer.

Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M, Reed SI.

Cancer Res. 2002 Aug 15;62(16):4535-9.

2.

Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma.

Cassia R, Moreno-Bueno G, Rodríguez-Perales S, Hardisson D, Cigudosa JC, Palacios J.

J Pathol. 2003 Dec;201(4):589-95.

PMID:
14648662
3.

Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line.

Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI.

Nature. 2001 Sep 20;413(6853):316-22.

PMID:
11565034
4.

Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer.

Ekholm-Reed S, Spruck CH, Sangfelt O, van Drogen F, Mueller-Holzner E, Widschwendter M, Zetterberg A, Reed SI.

Cancer Res. 2004 Feb 1;64(3):795-800. Erratum in: Cancer Res. 2004 Apr 15;64(8):2939. Reed, Susanna Ekholm [corrected to Reed-Ekholm, Susanna].

5.

Mutational analysis of the hCDC4 gene in gastric carcinomas.

Lee JW, Soung YH, Kim HJ, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH.

Eur J Cancer. 2006 Sep;42(14):2369-73.

PMID:
16824748
6.

SCF(Fbxw7/hCdc4) targets cyclin E2 for ubiquitin-dependent proteolysis.

Klotz K, Cepeda D, Tan Y, Sun D, Sangfelt O, Spruck C.

Exp Cell Res. 2009 Jul 1;315(11):1832-9. doi: 10.1016/j.yexcr.2008.11.017.

PMID:
19084516
7.

The Fbxw7/hCdc4 tumor suppressor in human cancer.

Tan Y, Sangfelt O, Spruck C.

Cancer Lett. 2008 Nov 18;271(1):1-12. doi: 10.1016/j.canlet.2008.04.036. Review.

PMID:
18541364
8.

Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms.

van Drogen F, Sangfelt O, Malyukova A, Matskova L, Yeh E, Means AR, Reed SI.

Mol Cell. 2006 Jul 7;23(1):37-48.

9.

Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.

Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, Hariharan IK, Harkin DP, Haber DA, Bell DW.

Gynecol Oncol. 2005 Jul;98(1):124-8.

PMID:
15913747
10.

The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.

Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, Heyman M, Spruck C, Grandér D, Lendahl U, Sangfelt O.

Cancer Res. 2007 Jun 15;67(12):5611-6. Erratum in: Cancer Res. 2008 Mar 15;68(6):2051. Akhondi, Shahab [corrected to Akhoondi, Shahab].

11.

MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression.

Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng HF, Akbari Moqadam F, Oude Vrielink JA, Agami R, Den Boer ML, Grandér D, Sangfelt O.

Cell Cycle. 2011 Jul 1;10(13):2172-83.

PMID:
21597324
12.

Cyclin E dysregulation and chromosomal instability in endometrial cancer.

Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, Müller HM, Goebel G, Mueller-Holzner E, Marth C, Spruck CH, Reed SI, Widschwendter M.

Oncogene. 2004 May 20;23(23):4187-92.

PMID:
15048079
13.

FBXW7/hCDC4 is a general tumor suppressor in human cancer.

Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C.

Cancer Res. 2007 Oct 1;67(19):9006-12. Erratum in: Cancer Res. 2008 Feb 15;68(4):1245. Dofou, Dimitra [corrected to Dafou, Dimitra].

14.

Fbw7 isoform interaction contributes to cyclin E proteolysis.

Zhang W, Koepp DM.

Mol Cancer Res. 2006 Dec;4(12):935-43.

15.

Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.

Fujii Y, Yada M, Nishiyama M, Kamura T, Takahashi H, Tsunematsu R, Susaki E, Nakagawa T, Matsumoto A, Nakayama KI.

Cancer Sci. 2006 Aug;97(8):729-36.

16.

Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells.

Willmarth NE, Albertson DG, Ethier SP.

Breast Cancer Res. 2004;6(5):R531-9.

17.

hCDC4 variation in osteosarcoma.

Yan T, Wunder JS, Gokgoz N, Seto KK, Bell RS, Andrulis IL.

Cancer Genet Cytogenet. 2006 Sep;169(2):138-42.

PMID:
16938571
18.

Inactivation of hCDC4 can cause chromosomal instability.

Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C.

Nature. 2004 Mar 4;428(6978):77-81.

19.

The FBXW7 beta-form is suppressed in human glioma cells.

Gu Z, Inomata K, Ishizawa K, Horii A.

Biochem Biophys Res Commun. 2007 Mar 23;354(4):992-8.

PMID:
17274947
20.

Triggering ubiquitination of a CDK inhibitor at origins of DNA replication.

Furstenthal L, Swanson C, Kaiser BK, Eldridge AG, Jackson PK.

Nat Cell Biol. 2001 Aug;3(8):715-22.

PMID:
11483956
Items per page

Supplemental Content

Support Center